With Rare Exceptions, Plans Stick With Generics for Epilepsy With Chart: Current Market Access to Epilepsy Medications

Pharmaceutical treatment for different types of epilepsy generally still relies on tried-and-true generics, despite recent efforts by drug manufacturers to introduce new branded medications into the mix, PBM insiders say.

Xcopri (cenobamate tablets) launched in May for the treatment of partial-onset seizures in adults. According to manufacturer SK Life Science, Inc., a subsidiary of SK Biopharmaceuticals Co., Ltd., clinical trials have shown “significant reductions in seizure frequency compared to placebo at all doses studied, and as many as one in five patients achieved zero seizures during the maintenance phase.”

© 2023 MMIT
Freelance Reporter

Freelance Reporter Freelance Reporter

Related Posts

doctor-speaking-to-a-patient
May 25

Commercial Insurance Restrictions Complicate Biosimilar Adoption

READ MORE
shell-game
May 25

‘Shell Game’ or Rebate Maximizers? FTC Probe Reignites Debate Over GPOs

Read More
pills-in-hand
May 25

As Weight Loss Drugs’ Star Rises, Plan Sponsors, Researchers Worry About Costs

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today